Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Syndax Pharmaceuticals, Inc. is not a good value stock. Syndax Pharmaceuticals, Inc. is not a good growth stock. Syndax Pharmaceuticals, Inc. is not very popular among insiders. Syndax Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include ca...
SNDX Fundamental Data by TradingView

News

Zurcher Kantonalbank Zurich Cantonalbank Has $251,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Zurcher Kantonalbank Zurich Cantonalbank Has $251,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Ticker Report Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 33.1% in the 2nd quarter, according to its most recent filing with the...\n more…

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass...\n more…

nVerses Capital LLC Invests $33,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
nVerses Capital LLC Invests $33,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Zolmax nVerses Capital LLC acquired a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the second quarter, according to its most recent disclosure with the Securities...\n more…

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Peregrine Capital Management LLC
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Peregrine Capital Management LLC

Zolmax Peregrine Capital Management LLC grew its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 1.3% in the second quarter, according to the company in its most recent 13F...\n more…

Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $35.33
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $35.33

Zolmax Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the firm, Marketbeat reports. One...\n more…

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts

Ticker Report Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has been given an average rating of "Moderate Buy" by the ten brokerages that are currently covering the stock, Marketbeat Ratings...\n more…